The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Enfortumab vedotin produced tumor response rate of 44% in bladder cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Astellas Pharma Inc. and Seattle Genetics Inc. announced data from the first cohort of a pivotal phase II clinical trial known as EV-201 demonstrated the investigational agent enfortumab vedotin rapidly shrank tumors in most patients, resulting in an objective response rate of 44% (55/125; 95% Confidence Interval: 35.1-53.2).

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

Moving from mandate to mission: Community outreach and engagement at NCI-designated cancer centers
“COE is broken.”

Acting Director Dr. Krzysztof Ptak’s words reverberated throughout the meeting room—and the heads of several of us—during the National Cancer Institute’s Office of Cancer Centers update on the final day of the 2024 Association of American Cancer Institutes/Cancer Center Administrators Forum Annual Meeting in Chicago.
By Monica L. Baskin, Nadine J. Barrett, Kim F. Rhoads, Hayley S. Thompson, Kimlin Tam Ashing, Folakemi T. Odedina and Vanessa B. Sheppard

Art exhibit at University of Miami Sylvester bridges North and South America

“Bridge to Bahia” exhibit.Source: Sylvester Comprehensive Cancer CenterKaren Estrada, a survivor of acute myeloid leukemia, used visual art to communicate with her two boys while undergoing a bone marrow transplant at Sylvester Comprehensive Cancer Center. Because Estrada’s treatment required isolation, and her young children could not yet read and write, she sought out other creative vessels to foster closeness between them.
By Claire Marie Porter
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account